These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 25972551)

  • 1. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research.
    Wieczorek L; Krebs SJ; Kalyanaraman V; Whitney S; Tovanabutra S; Moscoso CG; Sanders-Buell E; Williams C; Slike B; Molnar S; Dussupt V; Alam SM; Chenine AL; Tong T; Hill EL; Liao HX; Hoelscher M; Maboko L; Zolla-Pazner S; Haynes BF; Pensiero M; McCutchan F; Malek-Salehi S; Cheng RH; Robb ML; VanCott T; Michael NL; Marovich MA; Alving CR; Matyas GR; Rao M; Polonis VR
    J Virol; 2015 Aug; 89(15):7478-93. PubMed ID: 25972551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite Neutralizers.
    Schorcht A; van den Kerkhof TLGM; Cottrell CA; Allen JD; Torres JL; Behrens AJ; Schermer EE; Burger JA; de Taeye SW; Torrents de la Peña A; Bontjer I; Gumbs S; Ozorowski G; LaBranche CC; de Val N; Yasmeen A; Klasse PJ; Montefiori DC; Moore JP; Schuitemaker H; Crispin M; van Gils MJ; Ward AB; Sanders RW
    J Virol; 2020 Nov; 94(24):. PubMed ID: 32999024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.
    Lian Y; Srivastava I; Gómez-Román VR; Zur Megede J; Sun Y; Kan E; Hilt S; Engelbrecht S; Himathongkham S; Luciw PA; Otten G; Ulmer JB; Donnelly JJ; Rabussay D; Montefiori D; van Rensburg EJ; Barnett SW
    J Virol; 2005 Nov; 79(21):13338-49. PubMed ID: 16227256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies from Rabbits Immunized with HIV-1 Clade B SOSIP Trimers Can Neutralize Multiple Clade B Viruses by Destabilizing the Envelope Glycoprotein.
    van Haaren MM; McCoy LE; Torres JL; Lee W; Cottrell CA; Copps JL; van der Woude P; Yasmeen A; de Taeye SW; Torrents de la Peña A; Moore JP; Burton DR; Klasse PJ; Ward AB; Sanders RW; van Gils MJ
    J Virol; 2021 Aug; 95(17):e0009421. PubMed ID: 34076487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
    Kothe DL; Decker JM; Li Y; Weng Z; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Salazar-Gonzalez JF; Moldoveanu Z; Mestecky J; Gao F; Haynes BF; Shaw GM; Muldoon M; Korber BT; Hahn BH
    Virology; 2007 Mar; 360(1):218-34. PubMed ID: 17097711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
    Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
    PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity comparison between codon optimized HIV-1 CRF BC_07 gp140 and gp145 vaccines.
    Liu L; Wan Y; Xu J; Huang X; Wu L; Liu Y; Shao Y
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1396-404. PubMed ID: 18184083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies.
    Guenaga J; Alirezaei M; Feng Y; Alameh MG; Lee WH; Baboo S; Cluff J; Wilson R; Bale S; Ozorowski G; Lin P; Tam Y; Diedrich JK; Yates JR; Paulson JC; Ward AB; Weissman D; Wyatt RT
    Front Immunol; 2024; 15():1426232. PubMed ID: 39119336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broadly neutralizing antibodies against HIV-1: templates for a vaccine.
    van Gils MJ; Sanders RW
    Virology; 2013 Jan; 435(1):46-56. PubMed ID: 23217615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination.
    Dingens AS; Pratap P; Malone K; Hilton SK; Ketas T; Cottrell CA; Overbaugh J; Moore JP; Klasse PJ; Ward AB; Bloom JD
    Elife; 2021 Jan; 10():. PubMed ID: 33438580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad HIV-1 neutralizing antibody response induced by heterologous gp140/gp145 DNA prime-vaccinia boost immunization.
    Liu L; Hao Y; Luo Z; Huang Y; Hu X; Liu Y; Shao Y
    Vaccine; 2012 Jun; 30(28):4135-43. PubMed ID: 22561314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection.
    Ditse Z; Mkhize NN; Yin M; Keefer M; Montefiori DC; Tomaras GD; Churchyard G; Mayer KH; Karuna S; Morgan C; Bekker LG; Mlisana K; Gray G; Moodie Z; Gilbert P; Moore PL; Williamson C; Morris L
    mSphere; 2020 Jan; 5(1):. PubMed ID: 31996422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies.
    Sanders RW; Derking R; Cupo A; Julien JP; Yasmeen A; de Val N; Kim HJ; Blattner C; de la Peña AT; Korzun J; Golabek M; de Los Reyes K; Ketas TJ; van Gils MJ; King CR; Wilson IA; Ward AB; Klasse PJ; Moore JP
    PLoS Pathog; 2013 Sep; 9(9):e1003618. PubMed ID: 24068931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies.
    Dieltjens T; Heyndrickx L; Willems B; Gray E; Van Nieuwenhove L; Grupping K; Vanham G; Janssens W
    Retrovirology; 2009 Dec; 6():113. PubMed ID: 20003438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.
    Blish CA; Sather DN; Sellhorn G; Stamatatos L; Sun Y; Srivastava I; Barnett SW; Cleveland B; Overbaugh J; Hu SL
    J Virol; 2010 Mar; 84(5):2573-84. PubMed ID: 20015987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.
    Barnett SW; Lu S; Srivastava I; Cherpelis S; Gettie A; Blanchard J; Wang S; Mboudjeka I; Leung L; Lian Y; Fong A; Buckner C; Ly A; Hilt S; Ulmer J; Wild CT; Mascola JR; Stamatatos L
    J Virol; 2001 Jun; 75(12):5526-40. PubMed ID: 11356960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies.
    Ringe R; Phogat S; Bhattacharya J
    Virology; 2012 Apr; 426(1):34-41. PubMed ID: 22314018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
    Ferrantelli F; Maggiorella MT; Schiavoni I; Sernicola L; Olivieri E; Farcomeni S; Pavone-Cossut MR; Moretti S; Belli R; Collacchi B; Srivastava IK; Titti F; Cafaro A; Barnett SW; Ensoli B
    Vaccine; 2011 Apr; 29(16):2918-32. PubMed ID: 21338681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.
    Sharma VA; Kan E; Sun Y; Lian Y; Cisto J; Frasca V; Hilt S; Stamatatos L; Donnelly JJ; Ulmer JB; Barnett SW; Srivastava IK
    Virology; 2006 Aug; 352(1):131-44. PubMed ID: 21894641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.
    Wang S; Pal R; Mascola JR; Chou TH; Mboudjeka I; Shen S; Liu Q; Whitney S; Keen T; Nair BC; Kalyanaraman VS; Markham P; Lu S
    Virology; 2006 Jun; 350(1):34-47. PubMed ID: 16616287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.